Study on pharmacokinetic interactions between <scp>SHR2554</scp> and itraconazole in healthy subjects: A single‐center, open‐label phase I trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single‐center, open‐label phase I trial

Published:2022-07-16 Issue:2 Volume:12 Page:1431-1440
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Deng Kunhong¹,Zou Yi²,Zou Chan¹,Wang Hong²,Xiang Yuxia¹³,Yang Xiaoyan¹,Yang Shuang¹,Cui Chang¹,Yang Guoping¹³⁴⁵⁶^ORCID,Huang Jie¹³

Affiliation:

1. Center of Clinical Pharmacology The Third Xiangya Hospital, Central South University Changsha China

2. School of Mathematics and Statistics Central South University Changsha China

3. Research Center of Drug Clinical Evaluation of Central South University Changsha China

4. Department of Pharmacy The Third Xiangya Hospital, Central South University Changsha China

5. XiangYa School of Pharmaceutical Sciences Central South University Changsha China

6. National‐Local Joint Engineering Laboratory of Drug Clinical Evaluation Technology Changsha China

Funder

Key Research and Development Program of Hunan Province of China

National Natural Science Foundation of China

Jiangsu Hengrui Medicine

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5028

Reference34 articles.

1. EZH2 function in immune cell development

2. Emerging roles for Polycomb proteins in cancer

3. Post-translational modifications of EZH2 in cancer

4. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential

5. The role of EZH2 in tumour progression

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-target EZH2 inhibitor: latest advances in medicinal chemistry;Future Medicinal Chemistry;2024-07-31

2. Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR—EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer;Cancer Letters;2023-12

3. Use of histone methyltransferase inhibitors in cancer treatment: A systematic review;European Journal of Pharmacology;2023-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3